| Literature DB >> 26504095 |
Sophie Hayhoe1, Vilas Navapurkar1, Andrew Conway Morris2.
Abstract
A 42-year-old woman with end-stage renal failure was admitted to the intensive care unit following resuscitation from a pulseless electrical activity cardiac arrest after intravenous piperacillin/tazobactam. Persistent bradycardia and hypotension, unresponsive to epinephrine and norepinephrine, were suspected to have been exacerbated by chronic labetalol therapy for resistant arterial hypertension. As an alternative, the non-adrenergic inotrope, enoximone, was started. This, combined with thrombolysis for possible pulmonary embolism, heralded significant haemodynamic improvement, allowing weaning from inotropic support. A clear CT pulmonary angiogram 2 days post-arrest and significantly raised mast cell tryptase levels confirmed anaphylaxis rather than pulmonary embolism as the precipitating cause. We believe this to be the first case report of phosphodiesterase-III inhibitor use in the management of anaphylaxis complicated by α/β-blockade, and discuss the mechanism behind this effect and comparison with the more commonly reported use of glucagon. 2015 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26504095 PMCID: PMC4636698 DOI: 10.1136/bcr-2015-212432
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X